DarioHealth (DarioHealth) ROCE % : -76.31% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is DarioHealth ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. DarioHealth's annualized ROCE % for the quarter that ended in Dec. 2023 was -76.31%.

DarioHealth ROCE % Historical Data

The historical data trend for DarioHealth's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DarioHealth ROCE % Chart

DarioHealth Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-125.24

-125.32

-133.71

-64.77

-64.62

DarioHealth Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-46.64	-49.43	-56.23	-59.94	-76.31

DarioHealth ROCE % Calculation

DarioHealth's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-59.363	/	( ( (119.191 - 19.35)	+	(96.389 - 12.493) )	/ 2 )
	=	-59.363	/	( (99.841	+	83.896)	/ 2 )
	=	-59.363	/	91.8685
	=	-64.62 %

DarioHealth's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-69.556	/	( ( (106.505 - 8.106)	+	(96.389 - 12.493) )	/ 2 )
	=	-69.556	/	( ( 98.399	+	83.896 )	/ 2 )
	=	-69.556	/	91.1475
	=	-76.31 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

DarioHealth (NAS:DRIO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

DarioHealth ROCE % Related Terms

Thank you for viewing the detailed overview of DarioHealth's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

DarioHealth (DarioHealth) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DarioHealth Corp (NAS:DRIO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 W. 18th Street, New York, NY, USA, 10011

Website

https://www.mydario.com

DarioHealth Corp is a digital health company. It offers user-centric a multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally.

Executives

Jon H. Kaplan	director	1573 MALLORY LANE, SUITE 100, BRENTWOOD TN 37027
Erez Raphael	director, officer: Chief Executive Officer	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Dennis M Mcgrath	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Dror Bacher	officer: Chief Operating Officer	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK L3 3088900
Oded Cohen	officer: GM MSK	8 HATOKHEN ST., CAESAREA INDUSTRIAL PARK L3 3088900
Adam K Stern	director	STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Dennis Matheis	director	8 HATOKHEN ST., CAESAREA L3 38900
Yoav Shaked	director	8 HATOKHEN ST., CAESAREA L3 3088900
Yadin Shemmer	director	8 HATOKHEN ST., CAESAREA L3 3088900
Richard Allan Anderson	officer: President, GM of North America	C/O DARIOHEALTH CORP., 18 W. 18TH ST, 5TH FLOOR, NEW YORK NY 10011
Yalon Farhi	director	C/O LABSTYLE INNOVATIONS CORP., 9 HALAMISH ST., CAESAREA INDUSTRIAL PARK, CAESAREA L3 3088900
Hila Karah	director	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Zvi Ben-david	officer: Chief Financial Officer	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Glen Moller	director	8 HATOKHEN ST., CAESAREA L3 3088900
Olivier Roger Jarry	officer: See Remarks	15 ROCKRIDGE RD, LARCHMONT NY 10538-3918